Buy Dr. Reddy’s Labs; target of Rs 3360: HDFC Securities

HDFC Securities is bullish on Dr. Reddy’s Labs has recommended buy rating on the stock with a target price of Rs 3360 in its research report dated July 30, 2019.

Broker Research

July 31, 2019 / 11:23 IST

26 Aug, 2025 12:21

Volume

Todays L/H

HDFC Securities' research report on Dr. Reddy’s Labs

Revenue grew 3% YoY/ declined 4% QoQ with a good set of numbers for the India, EU, and US segments. A sharp decline in PSAI revenues and margin driven by manufacturing issues, and product related provisions for the US hampered revenue growth and profitability. However, this has been resolved in 2QFY20. The mgmt maintains normalized gross margin guidance (53-56%) for the coming quarters. Healthy growth in key regulated markets and improvement in product mix with complex generics/ biosimilars (EM)/ injectables (US) launches will drive EBITDA margin recovery (+200bps over FY19-21E to ~24%). At US$ 233mn, US grew ~9% QoQ aided by new launches, higher volumes in the base biz, and traction gained in gSuboxone; despite persisting pricing pressure. Following regulatory clearance for key plants, the co has launched 10 products in the US FYTD and aims 30+ launches for the full year. Key launches like gNuvaring/gCopaxone in FY20/21E and a better pricing environment will drive ~19% CAGR in the US. In other segments, India/EU/ROW grew 15/19/28% YoY. Expect healthy growth to continue, aided by new launches, growth in the base biz, continued ramp up in China, further supply improvements in EU and Russia, and sales force effectiveness in India.

Outlook

We maintain BUY on DRRD following a miss on our estimates driven by temporary issues. Our TP is unchanged at Rs 3,360 (20x FY21E EPS + Rs 380/sh for niche products). A visible ramp up in the US and further cost efficiencies enable us to stay confident.

For all recommendations report, click here